Member? Please login
Not a member?
Sorry, this is a member only event.
Drug Lag and Loss: Japan’s Prescription for Progress
Thursday 06 Feb | 12.00 - 13.30
Join us for a thought-provoking discussion on the state of Japan's pharmaceutical industry. This panel discussion will delve into the challenges of drug loss and drug lag, exploring the root causes and potential solutions.
Location
Price
Members: ¥3,500
Non Members: ¥5,000
Written by Yousef
With Japan facing increasing pressure to balance healthcare affordability with innovation, challenges such as drug lag and pricing policies are more critical than ever. As the global pharmaceutical landscape evolves and healthcare demands grow and technological advancements accelerate, Japan must navigate these issues to remain competitive and foster advancements in healthcare.
The BCCJ invites you to a timely lunchtime event on Thursday, February 6 at the AstraZeneca KK office, examining the current and future state of drug development and approval in Japan, and how this compares to the UK. Our panel of experts will explore how regulatory frameworks, innovation ecosystems, public-private partnerships, and international collaboration can address these pressing challenges and unlock new opportunities.
This event is designed for industry professionals, policymakers, researchers, and anyone interested in the future of healthcare in Japan and synergies in healthcare innovation between Japan and the UK.
Panellists
Philippe Fauchet, O.B.E | Founder | Mirasense Partners
Philippe has spent 35+ years in the Pharmaceutical Industry, mostly in Japan and Korea as a general manager for Sanofi and then GSK. He is the founder of Mirasense Partners, a provider consulting services for Life Sciences Companies, as well as Venture Partner at 4BioCapital investment fund (UK) and External Director on the Board of Biotech companies in Japan and in the USA. He is a Director on the Board of MEJ (Medical Excellence Japan).
Philippe serves as Senior Advisor to EFPIA. He is also appointed French Foreign Trade Honorary Advisor (CCE) and is an Affiliate Senior Research Fellow of the Tokyo Foundation for Policy Research and a mentor for Link-J Unikorn program for Japanese startups. He was awarded Honorary Officer of the Most Excellent Order of the British Empire (O.B.E.) in 2014.
Philippe Fauchet, O.B.E | Founder | Mirasense Partners
Philippe has spent 35+ years in the Pharmaceutical Industry, mostly in Japan and Korea as a general manager for Sanofi and then GSK. He is the founder of Mirasense Partners, a provider consulting services for Life Sciences Companies, as well as Venture Partner at 4BioCapital investment fund (UK) and External Director on the Board of Biotech companies in Japan and in the USA. He is a Director on the Board of MEJ (Medical Excellence Japan).
Philippe serves as Senior Advisor to EFPIA. He is also appointed French Foreign Trade Honorary Advisor (CCE) and is an Affiliate Senior Research Fellow of the Tokyo Foundation for Policy Research and a mentor for Link-J Unikorn program for Japanese startups. He was awarded Honorary Officer of the Most Excellent Order of the British Empire (O.B.E.) in 2014.
Kenji Shibuya | CEO | Medical Excellence Japan
Professor Kenji Shibuya is a renowned expert in global and population health. He has held pivotal roles, including Professor at King’s College London and the University of Tokyo. Dr. Shibuya has shaped Japanese health policies, contributed to G7 health summits, and led initiatives like Health Care 2035. He has advised governments, private sectors, and civil societies, and served as Senior Advisor to the WHO Director-General and on CEPI’s Scientific Advisory Committee. Currently, he is CEO of Medical Excellence JAPAN, Research Director at the Tokyo Foundation for Policy Research, and Venture Partner at Eight Rodas Ventures Japan.
Kenji Shibuya | CEO | Medical Excellence Japan
Professor Kenji Shibuya is a renowned expert in global and population health. He has held pivotal roles, including Professor at King’s College London and the University of Tokyo. Dr. Shibuya has shaped Japanese health policies, contributed to G7 health summits, and led initiatives like Health Care 2035. He has advised governments, private sectors, and civil societies, and served as Senior Advisor to the WHO Director-General and on CEPI’s Scientific Advisory Committee. Currently, he is CEO of Medical Excellence JAPAN, Research Director at the Tokyo Foundation for Policy Research, and Venture Partner at Eight Rodas Ventures Japan.
Takafumi Horii | President & Representative Director | AstraZeneca K.K.
Prior to his role at AstraZeneca K.K., Taka served as Senior Vice President, Head of Japan Oncology Business Unit and a member of the Global Oncology Leadership Team, as well as being part of the Japan Country Committee at Takeda Pharmaceutical Company. Previously, Taka held various leadership roles at Takeda across the world, including VP & Area Head of the Near-east, Middle-east and Africa covering 21 countries in the region, President & General Manager in Taiwan, VP & Head of Strategy of Emerging Market, and Head of Strategy for China.
Takafumi Horii | President & Representative Director | AstraZeneca K.K.
Prior to his role at AstraZeneca K.K., Taka served as Senior Vice President, Head of Japan Oncology Business Unit and a member of the Global Oncology Leadership Team, as well as being part of the Japan Country Committee at Takeda Pharmaceutical Company. Previously, Taka held various leadership roles at Takeda across the world, including VP & Area Head of the Near-east, Middle-east and Africa covering 21 countries in the region, President & General Manager in Taiwan, VP & Head of Strategy of Emerging Market, and Head of Strategy for China.
Alison Beale | Director Japan Office | University of Oxford [moderator]
After graduating from the University of Oxford she first came to Japan on the JET Programme before embarking on a career in international cultural relations principally with the British Council, holding senior posts in Japan, Trinidad and Tobago and China. She also obtained a Masters in Advanced Japanese Studies from the University of Sheffield. In her current role with the University of Oxford she develops links and partnerships for the University with businesses, foundations, alumni and media in Japan.
Alison Beale | Director Japan Office | University of Oxford [moderator]
After graduating from the University of Oxford she first came to Japan on the JET Programme before embarking on a career in international cultural relations principally with the British Council, holding senior posts in Japan, Trinidad and Tobago and China. She also obtained a Masters in Advanced Japanese Studies from the University of Sheffield. In her current role with the University of Oxford she develops links and partnerships for the University with businesses, foundations, alumni and media in Japan.
NOTES:
Meal: Lunch will be served at this event. Please indicate any specific dietary requirements at the time of booking.
Cancellation policy: For reservations made after Thursday, January 30 at 17.00, there will be no refunds on cancellations. Please note, no-shows will be charged in full, and we are unable to accept cash payments at the door.
お食事：アレルギーなどお食事制限のある方は必ず事前にお知らせください。当日の変更はお受けできません。
申込みとキャンセル・お支払い：お申し込みと同時にご送金をお願いいたします。締切り日1月30日（木）17.00 以後のキャンセル・返金はお受けできませんので、ご留意ください。お名前の変更のみ、お受けいたします。
締切りまでにキャンセルのご連絡なく、当日欠席された場合にも、参加費はお支払いただきますので、ご協力をお願いいたします。当日のお支払いは固くお断りいたします。
